Clinical Trial Update: Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (PCS X) is investigating management of oligoprogressive metastatic castration-resistant prostate cancer, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Snippet

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital | Conditions: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING